{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Everolimus", "Ischemic stroke", "Middle cerebral artery occlusion (MCAO)", "Neuroprotection", "Oxidative stress"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35633587", "DateCompleted": {"Year": "2022", "Month": "07", "Day": "26"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "26"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "05", "Day": "25"}], "Language": ["eng"], "ELocationID": ["10.1016/j.jstrokecerebrovasdis.2022.106576", "S1052-3057(22)00270-1"], "Journal": {"ISSN": "1532-8511", "JournalIssue": {"Volume": "31", "Issue": "8", "PubDate": {"Year": "2022", "Month": "Aug"}}, "Title": "Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association", "ISOAbbreviation": "J Stroke Cerebrovasc Dis"}, "ArticleTitle": "Neuroprotection of Everolimus Against Focal Cerebral Ischemia-Reperfusion Injury in Rats.", "Pagination": {"StartPage": "106576", "MedlinePgn": "106576"}, "Abstract": {"AbstractText": ["Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth and metabolism and integrates various signals under physiological and pathological conditions. Altered signaling of mTOR has been shown to play pathogenic roles in ischemic stroke. In the present study, the protective effect of everolimus, the selective mTOR inhibitor, in the middle cerebral artery occlusion (MCAO) model of ischemic stroke was evaluated.", "Wistar rats were exposed to MCAO (30 min) followed by reperfusion for 24 h. Everolimus (100, and 500\u2009\u00b5g/kg) was administered at the time of reperfusion, intraperitoneally. 24 h post operation, the neurological function, infarct volume, histopathological alterations and the markers of oxidative stress including superoxide dismutase (SOD) activity, malondialdehyde (MDA), and total thiol levels were analyzed in the peri-infarct region.", "In the rats subjected to MCAO, everolimus ameliorated neurological deficits, neuronal cell loss, and infarct volume, as compared to the stroke group. Also, everolimus significantly increased SOD activity and total thiol content, while markedly decreased the MDA level, as compared to MCAO group.", "Single-dose administration of everolimus significantly improved neurological deficits and inhibited cortical cell loss by enhancing redox status, subsequently protected cerebral ischemia-reperfusion injury in rats."], "CopyrightInformation": "Copyright \u00a9 2022 Elsevier Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Forouzanfar", "ForeName": "Fatemeh", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Ebrahimi", "ForeName": "Payam Razavi", "Initials": "PR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran; Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sadeghniahr@mums.ac.ir."}], "LastName": "Sadeghnia", "ForeName": "Hamid Reza", "Initials": "HR"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Stroke Cerebrovasc Dis", "NlmUniqueID": "9111633", "ISSNLinking": "1052-3057"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfhydryl Compounds"}, {"RegistryNumber": "9HW64Q8G6G", "NameOfSubstance": "Everolimus"}, {"RegistryNumber": "EC 1.15.1.1", "NameOfSubstance": "Superoxide Dismutase"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "TOR Serine-Threonine Kinases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Brain Injuries"}, {"QualifierName": ["drug therapy", "pathology", "prevention & control"], "DescriptorName": "Brain Ischemia"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Everolimus"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Infarction, Middle Cerebral Artery"}, {"QualifierName": [], "DescriptorName": "Ischemic Stroke"}, {"QualifierName": ["metabolism"], "DescriptorName": "Mammals"}, {"QualifierName": [], "DescriptorName": "Neuroprotection"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": [], "DescriptorName": "Reperfusion"}, {"QualifierName": ["prevention & control"], "DescriptorName": "Reperfusion Injury"}, {"QualifierName": [], "DescriptorName": "Sulfhydryl Compounds"}, {"QualifierName": ["metabolism"], "DescriptorName": "Superoxide Dismutase"}, {"QualifierName": ["metabolism"], "DescriptorName": "TOR Serine-Threonine Kinases"}], "CoiStatement": "Declaration of Competing Interest None"}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2021", "Month": "11", "Day": "28"}, {"Year": "2022", "Month": "5", "Day": "1"}, {"Year": "2022", "Month": "5", "Day": "15"}, {"Year": "2022", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "28", "Hour": "18", "Minute": "2"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35633587", "10.1016/j.jstrokecerebrovasdis.2022.106576", "S1052-3057(22)00270-1"]}}], "PubmedBookArticle": []}